| In millions, except per share items | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 | Dec-31-13 | Dec-31-12 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| Prescription Pharmaceuticals | 604.2 | 620.7 | 772.5 | | 924.5 | 504.7 | 279.9 | 223.9 |
| Consumer Health | 78.2 | 73.3 | 68.5 | | 60.6 | 50.4 | 37.8 | 32.3 |
| Total revenues | 682.4 | 694.0 | 841.0 | 1,116.8 | 985.1 | 555.0 | 317.7 | 256.2 |
| Revenue growth [+] | -1.7% | -17.5% | -24.7% | 13.4% | 77.5% | 74.7% | 24.0% | 87.1% |
| Prescription Pharmaceuticals | -2.7% | -19.7% | | | 83.2% | 80.3% | 25.0% | |
| Consumer Health | 6.6% | 7.0% | | | 20.3% | 33.2% | 17.1% | |
| Cost of goods sold | 429.7 | 448.0 | 408.8 | 443.3 | 389.1 | 293.7 | 145.8 | 107.5 |
| Gross profit | 252.7 | 246.0 | 432.2 | 673.5 | 596.0 | 261.4 | 171.9 | 148.7 |
| Gross margin | 37.0% | 35.4% | 51.4% | 60.3% | 60.5% | 47.1% | 54.1% | 58.0% |
| Selling, general and administrative [+] | 85.8 | 279.7 | 216.5 | 197.6 | 162.2 | 93.0 | 53.5 | 48.1 |
| Sales and marketing | -188.1 | | | | | | | |
| Other selling, general and administrative | 273.9 | | | | | | | |
| Research and development | 37.5 | 47.3 | 45.0 | 38.8 | 40.7 | 31.3 | 19.9 | 15.9 |
| Equity in earnings | | | | | | | 0.1 | |
| Other operating expenses | 188.1 | | | 65.7 | 66.3 | 43.5 | 7.4 | 6.9 |
| EBITDA [+] | -28.2 | -51.7 | 194.5 | 459.4 | 413.8 | 151.5 | 105.7 | 89.4 |
| EBITDA growth | -45.5% | -126.6% | -57.7% | 11.0% | 173.1% | 43.4% | 18.2% | 66.1% |
| EBITDA margin | -4.1% | -7.5% | 23.1% | 41.1% | 42.0% | 27.3% | 33.3% | 34.9% |
| Depreciation and amortization | 30.5 | 29.3 | 23.7 | 22.3 | 20.7 | 14.3 | 7.1 | 4.6 |
| EBITA | -58.7 | -81.1 | 170.7 | 437.1 | 393.1 | 137.1 | 98.6 | 84.8 |
| EBITA margin | -8.6% | -11.7% | 20.3% | 39.1% | 39.9% | 24.7% | 31.0% | 33.1% |
| Amortization of intangibles | 39.8 | 53.5 | 61.4 | 65.7 | 66.3 | 43.5 | 7.4 | 6.9 |
| EBIT [+] | -98.5 | -134.5 | 109.3 | 371.4 | 326.8 | 93.7 | 91.2 | 77.9 |
| EBIT growth | -26.8% | -223.1% | -70.6% | 13.6% | 249.0% | 2.7% | 17.1% | 60.4% |
| EBIT margin | -14.4% | -19.4% | 13.0% | 33.3% | 33.2% | 16.9% | 28.7% | 30.4% |
| Non-recurring items [+] | 89.6 | 253.9 | 132.2 | 48.6 | 32.2 | 32.8 | 2.9 | 9.2 |
| Asset impairment | 45.5 | 231.1 | 128.1 | 44.4 | 30.4 | | | |
| Loss (gain) on sale of assets | | | | | | 9.3 | | |
| Legal settlement | 44.2 | 22.8 | 4.0 | 3.8 | | | | |
| Interest expense | 69.4 | 45.9 | 38.1 | 44.1 | 54.8 | 35.7 | 8.6 | 10.5 |
| Interest expense | 69.4 | 45.9 | 38.1 | 44.1 | 54.8 | 35.7 | 8.6 | 10.5 |
| Other income (expense), net [+] | -30.3 | -3.9 | 1.8 | -7.5 | -7.7 | 0.2 | 3.3 | -0.8 |
| Amortization of financing costs and debt discount | -31.6 | -5.2 | -5.2 | -10.8 | -4.3 | -10.0 | -0.8 | -0.8 |
| Gain (loss) on sale of assets | | | | | | 9.3 | | |
| Gain (loss) on acquisitions / transactions | | | | | 0.8 | | 3.7 | |
| Other | 1.2 | 1.4 | 7.0 | 2.0 | -7.0 | 0.9 | 0.4 | |
| Pre-tax income | -287.8 | -438.2 | -59.2 | 271.3 | 232.2 | 25.3 | 82.9 | 57.5 |
| Income taxes | -61.0 | -36.3 | -34.6 | 87.1 | 81.4 | 11.0 | 30.5 | 22.1 |
| Tax rate | 21.2% | 8.3% | 58.5% | 32.1% | 35.0% | 43.2% | 36.8% | 38.5% |
| Net income | -287.8 | -438.2 | -59.2 | 271.3 | 150.8 | 13.9 | 52.4 | 35.4 |
| Net margin | -42.2% | -63.1% | -7.0% | 24.3% | 15.3% | 2.5% | 16.5% | 13.8% |
| |
| Basic EPS [+] | ($2.28) | ($3.49) | ($0.47) | $2.21 | $1.29 | $0.14 | $0.54 | $0.37 |
| Growth | -34.6% | 636.7% | -121.5% | 71.3% | 827.1% | -74.5% | 46.5% | -18.3% |
| Diluted EPS [+] | ($2.28) | ($3.49) | ($0.47) | $2.16 | $1.20 | $0.13 | $0.46 | $0.32 |
| Growth | -34.6% | 636.7% | -122.0% | 79.9% | 813.3% | -71.4% | 43.6% | -22.7% |
| |
| Shares outstanding (basic) [+] | 126.0 | 125.4 | 124.8 | 122.9 | 117.0 | 103.5 | 96.2 | 95.2 |
| Growth | 0.5% | 0.5% | 1.6% | 5.0% | 13.0% | 7.6% | 1.0% | 0.7% |
| Shares outstanding (diluted) [+] | 126.0 | 125.4 | 124.8 | 125.8 | 125.8 | 109.6 | 113.9 | 110.5 |
| Growth | 0.5% | 0.5% | -0.8% | 0.0% | 14.8% | -3.8% | 3.1% | 6.3% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |